期刊文献+

中性粒细胞/淋巴细胞值、血小板/淋巴细胞值、淋巴细胞/单核细胞值对食管癌根治术后吻合口瘘的预测价值 被引量:8

Predictive value of postoperative anastomotic leakage in radical surgery for esophageal carcinoma using neutrophil/lymphocyte,platelet/lymphocyte,and lymphocyte/monocyte ratios
下载PDF
导出
摘要 目的探讨中性粒细胞/淋巴细胞值(NLR)、血小板/淋巴细胞值(PLR)、淋巴细胞/单核细胞值(LMR)食管癌根治术前后的变化对术后发生吻合口瘘的预测价值。方法回顾性分析在中国医科大学附属盛京医院行食管癌根治术的182例患者及其术前NLR和手术前后NLR的变化值,PLR和手术前后PLR的变化值,LMR和手术前后LMR的变化值。同时比较其他相关因素,包括年龄、是否合并糖尿病等,应用统计学分析NLR、PLR、LMR和手术前后变化值对术后吻合口瘘的预测价值。结果合并糖尿病、手术前后NLR变化值≥3.36、手术前后PLR变化值≥2.26是食管癌根治术后并发吻合口瘘的独立危险因素(P<0.05)。结论手术前后NLR、PLR变化值对食管癌根治术后并发吻合口瘘具有预测价值。 Objective To explore the predictive value of neutrophil/lymphocyte ratio(NLR),platelet/lymphocyte ratio(PLR),lymphocyte/monocyte ratio(LMR)and their changes for the occurrence of anastomotic fistula after radical resection for esophageal cancer.Methods This is a retrospective analysis of 182 patients who underwent radical resection of esophageal cancer in Shengjing Hospital of China Medical University.We selected preoperative NLR,PLR,and LMR and their changes before and after surgery as observation indicators.At the same time,other related factors,including age,diabetes status,etc.,were compared.We used the data of NLR,PLR,LMR,and changes before and after the operation to analyze the predictive value for postoperative anastomotic leakage.Results Diabetes,NLR change before and after operation≥3.36,and PLR change before and after operation≥2.26 are independent risk factors for anastomotic leakage after radical resection of esophageal cancer(P<0.05).Conclusion Changes in NLR and PLR before and after the surgery have predictive value for anastomotic leakage after radical resection of esophageal cancer.
作者 俞越 韩云 YU Yue;HAN Yun(Department of the Second Thoracic Surgery,Shengjing Hospital of China Medical University,Shenyang 110004,China)
出处 《中国医科大学学报》 CAS CSCD 北大核心 2021年第9期799-803,共5页 Journal of China Medical University
基金 辽宁省自然科学基金(20180530020)。
关键词 食管癌根治术 术后吻合口瘘 中性粒细胞/淋巴细胞值 血小板/淋巴细胞值 淋巴细胞/单核细胞值 esophagectomy postoperative anastomotic leakage neutrophil/lymphocyte ratio platelet/lymphocyte ratio lymphocyte/monocyte ratio
  • 相关文献

参考文献4

二级参考文献81

  • 1顾恺时.顺恺时胸心外科手术学[M].上海:上海科学技术出版社,2003:941.
  • 2Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, RosenbergHM, Vernon SW, Cronin K, Edwards BK. The annual reportto the nation on the status of cancer, 1973-1997, with a specialsection on colorectal cancer. Cancer 2000; 88: 2398-2424 [PMID:10820364 DOI: 10.1002/(SICI)1097-0142(20000515)88:10<2398::AIDCNCR26>3.0.CO;2-I].
  • 3Simmonds PC. Palliative chemotherapy for advanced colorectalcancer: systematic review and meta-analysis. Colorectal CancerCollaborative Group. BMJ 2000; 321: 531-535 [PMID: 10968812DOI: 10.1136/bmj.321.7260.531].
  • 4Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survivalof patients with advanced colorectal cancer improves with theavailability of fluorouracil-leucovorin, irinotecan, and oxaliplatin inthe course of treatment. J Clin Oncol 2004; 22: 1209-1214 [PMID:15051767 DOI: 10.1200/JCO.2004.11.037].
  • 5Saltz LB, Clarke S, Dz-Rubio E, Scheithauer W, Figer A, WongR, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, SirzF, Cassidy J. Bevacizumab in combination with oxaliplatin-basedchemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019[PMID: 18421054 DOI: 10.1200/JCO.2007.14.9930].
  • 6Van Cutsem E, Kne CH, Hitre E, Zaluski J, Chang Chien CR,Makhson A, D'aens G, Pint T, Lim R, Bodoky G, Roh JK,Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J,Rougier P. Cetuximab and chemotherapy as initial treatment formetastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417[PMID: 19339720 DOI: 10.1056/NEJMoa0805019].
  • 7Chibaudel B, Tournigand C, Andr-T, de Gramont A. Therapeuticstrategy in unresectable metastatic colorectal cancer. Ther Adv MedOncol 2012; 4: 75-89 [PMID: 22423266 DOI: 10.1177/1758834011431592].
  • 8Sobin L, Gospodarowicz M, Wittekind C. International againstCancer. TNM classification of malignant tumors, 7th ed. New York:Wiley-Blackwell, 2009: 73-77.
  • 9Kang SM, Maeda K, Onoda N, Chung YS, Nakata B, NishiguchiY, Sowa M. Combined analysis of p53 and vascular endothelialgrowth factor expression in colorectal carcinoma for determinationof tumor vascularity and liver metastasis. Int J Cancer 1997; 74:502-507 [PMID: 9355971 DOI: 10.1002/(SICI)1097-0215(19971021)74:5<502::AID-IJC4>3.0.CO;2-7].
  • 10Maeda K, Chung YS, Takatsuka S, Ogawa Y, Sawada T, YamashitaY, Onoda N, Kato Y, Nitta A, Arimoto Y. Tumor angiogenesis as apredictor of recurrence in gastric carcinoma. J Clin Oncol 1995; 13:477-481 [PMID: 7531224].

共引文献25

同被引文献73

引证文献8

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部